原發(fā)性肺癌（簡稱肺癌）是常見的惡性腫瘤之一，發(fā)生率居惡性腫瘤首位。非小細胞肺癌（NSCLC）約占所有肺癌的80%。近年來，表皮生長因子受體–酪氨酸激酶抑制（EGFR-TKI）在NSCLC治療中起到重要作用；隨著EGFR-TKI在臨床上的廣泛應用，耐藥問題日益加劇；T790M基因突變是導致EGFR-TKI獲得性耐藥最主要的機制。全球新批準并上市的治療NSCLC EGFR-T790M突變的藥物有brigatinib、奧莫替尼、atezolizumab等；處于上市申請階段的有丁磺氨酸、阿拉莫林鹽酸鹽、ABP-215；處于研發(fā)階段的主要有naquotinib、TG-4010等。對近年來處于研發(fā)后期的NSCLC治療藥物進行詳細介紹，同時對抗NSCLC藥物的未來發(fā)展方向進行了展望，以期為抗NSCLC藥物的研發(fā)提供參考。

Primary lung cancer (referred to as lung cancer) is one of the common malignant tumors, and the incidence ranks the first of malignant tumors. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancer. In recent years, epidermal growth factor receptor-tyrosine kinase inhibition (EGFR-TKI) plays an important role in the treatment of NSCLC. With the extensive application of EGFR-TKI in clinical practice, the resistance problem is increasing. T790M gene mutation is leading to EGFR-TKI acquired resistance to the most important mechanism. Newly approved and marketed drugs for the treatment of NSCLC EGFR-T790M mutations include brigatinib, olmutinib, atezolizumab, etc.; Butylene acid, anamorelin hydrochloride and ABP-215 are in abbreviated new drug application, and naquotinib and TG-4010 are under development. The development of NSCLC in late development in recent years has been described in detail, and the future development direction of NSCLC drugs is also discussed in order to provide reference for the development of anti-NSCLC drugs.